CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast...
Phase 2
Valencia, Spain and 72 other locations
This trial is a Phase 2 neoadjuvant study evaluating ARV-471 or anastrozole in post-menopausal women with ER+/HER2- localized breast cancer...
Phase 2
Valencia, Spain and 48 other locations
A phase 1b study to assess the combination of ARV-471 and everolimus in participants with advanced or metastatic ER+/HER2- breast cancer...
Phase 1
Valencia, Spain and 8 other locations
-positive / HER2-negative breast cancer which has spread beyond the original tumor and/or to other organs.During this study, anti-h...
Phase 3
Valencia, Spain and 52 other locations
This program initially aims to recruit 1300 breast cancer patients from a large number of hospitals across Europe. Eligible patient...
Valencia, Spain and 51 other locations
This study will compare DS 8201a to standard treatment.Participants must have HER2 breast cancer that has been treated before.Their ...
Phase 3
Valencia, Spain and 226 other locations
participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast...
Phase 2
Valencia, Spain and 19 other locations
A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER Positive, HER2 Negative Advanced Breast Ca...
Phase 1
Valencia, Spain and 16 other locations
to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast...
Phase 3
Valencia, Spain and 114 other locations
Immune checkpoint inhibitors given in monotherapy in advanced breast cancer have shown modest benefit in first-line, but very limit...
Phase 2
Alicante, Spain and 14 other locations
Clinical trials
Research sites
Resources
Legal